NPSP NPS Pharmaceuticals, Inc., featured news, full reports, and detailed NPSP.O charts.
NPS Pharmaceuticals, Inc. (NPSP) Wrap Up:
We are a biopharmaceutical company engaged in the development of specialty therapeutics to treat gastrointestinal (GI) and endocrine disorders with high unmet medical need. Our lead clinical programs involve two proprietary proteins to restore or replace biological function: GATTEX⢠(teduglutide) and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection). GATTEX is an analog of GLP-2, a protein involved in the regeneration and repair of the intestinal lining, and is in Phase 3 clinical development for short bowel syndrome (SBS). SBS affects patients who have had 50% or more of their small intestine removed. Given GATTEX's activity in promoting gastrointestinal repair, we are also evaluating its role in treating other GI conditions associated with intestinal failure, specifically GI mucositis (GIM), necrotizing enterocolitis (NEC), and Crohn's disease. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f05%2f19%2f0001136261-08-000084.html#FIS_BUSINESS"
NPS Pharmaceuticals, Inc. (NPSP:NASDAQ)
Snapshot of NPS Pharmaceuticals, Inc. (NPSP)
|
OPEN
$3.09
|
PREVIOUS CLOSE
$3.10
|
|
|
DAY HIGH
$3.12
|
DAY LOW
$3.01
|
|
|
52 WEEK HIGH
12/9/08 - $7.00
|
52 WEEK LOW
06/1/09 - $2.74
|
|
|
MARKET CAP
151.1M
|
AVERAGE VOLUME 3 mo
302.6K
|
|
|
DILUTED EPS TTM
$-0.51
|
SHARES OUTSTANDING
48.4M
|
|
|
NPSP Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
NPSP Details
NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of specialty therapeutics for gastrointestinal and endocrine disorders. The company is advancing two late-stage programs to restore or replace biological function, including GATTEX (teduglutide), which is in Phase 3 clinical development for parenteral dependent short bowel syndrome; and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) that is in Phase 3 clinical development as a hormone therapy for hypoparathyroidism. It complements its internal programs with strategic partnerships with Amgen, GlaxoSmithKline, Kyowa Kirin, and Nycomed. The company was founded in 1986 and is headquartered in Bedminster, New Jersey.
NPSP Top Compensated Officers
Executives, Board Directors
Key developments for NPS Pharmaceuticals, Inc. (NPSP)
NPS Pharmaceuticals Inc. reported earnings results for third quarter and nine months ended September 30, 2009. For the quarter, the company reported operating income of $3,964,000, interest income $374,000, loss before income tax benefit $7,801,000, net loss of $7,766,000 or $0.16 diluted earnings per share on revenues of $20,119,000 compared to operating income of $14,545,000, interest income $983,000, loss before income tax benefit $11,482,000, net loss of $11,359,000 or $0.24 diluted earnings per share on revenues of $26,075,000, for the same period a year ago. For the nine months, the company reported operating income of $23,668,000, interest income $1,374,000, loss before income tax benefit $16,934,000, net loss of $15,885,000 or $ 0.33 diluted earnings per share on revenues of $62,097,000 compared to operating income of $35,967,000, interest income $3,804,000, loss before income tax benefit $23,469,000, net loss of $23,249,000 or $0.49 diluted earnings per share on revenues of $78,214,000, for the same period a year ago.
NPS Pharmaceuticals, Inc., Q3 2009 Earnings Call, Nov-04 2009
NPS Pharmaceuticals, Inc. expected to Report Fiscal Year 2009 Results on March 8, 2010. This event was calculated by Capital IQ (Created on October 29, 2009).
NPSP Competitors
| Company | Last | Change | |
| No competitor information is available for NPSP. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | NPSP | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 1.6x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | NM | Not Meaningful |
|
NPSP |
||
NPSP transactions
| Type Date |
Target |
|
Private Placement
August 5, 2009 |
-- |
More Recent News About NPS Pharmaceuticals, Inc.
-
NPS Pharmaceuticals Reports Third Quarter Results and Improved Cash Burn Guidance
HASH(0x2a966bdc90) -- Conference call today at 5:00 PM ET -- BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (NASDAQ:...
Business Wire, 11/04/09 · More from publication